A cost-effectiveness analysis of early detection and bundled treatment of postpartum hemorrhage alongside the E-MOTIVE trial.

Name: Αlpha¹ Rigor Record — A cost-effectiveness analysis of early detection and bundled treatment of postpartum hemorrhage alongside the E-MOTIVE trial.
Item: A cost-effectiveness analysis of early detection and bundled treatment of postpartum hemorrhage alongside the E-MOTIVE trial.
Rating: 100
Author: Αlpha¹

Williams EV, Goranitis I, Oppong R, Perry SJ, Devall AJ, Martin JT, Mammoliti KM, Beeson LE, Sindhu KN, Galadanci H, Alwy Al-Beity F, Qureshi Z, Hofmeyr GJ, Moran N, Fawcus S, Mandondo S, Middleton L, Hemming K, Oladapo OT, Gallos ID, Coomarasamy A, Roberts TE

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3.25★ (Adequate), 0 critical, 3 high issues for “A cost-effectiveness analysis of early detection and bundled treatment of postpartum hemorrhage alongside the E-MOTIVE trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3.25 / 5

Adequate — real issues to address

Observational Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
LinksDead data/code link−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced5 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions3

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

Broken references and links1

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Dead data/code linksRecomputed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted economic evaluation alongside a cluster-randomized trial, with strong reporting of methods, ethics, and data/code availability. Minor reporting gaps include lack of explicit blinding statement, power analysis details, and a small inconsistency in the usual-care group N between text and table.

The study type is classified as observational (economic evaluation) rather than interventional, as it analyzes trial data without conducting a new intervention. The reviewers diverged on study type (one said observational, one said interventional); the economic evaluation is a secondary analysis of trial data, so observational is more accurate. Biological variables and several sub-criteria (e.g., blinding, power analysis) are not applicable or not fully reported but do not affect the overall pass.

5 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

1 integrity concern flagged (0 high).

Reporting

Eight Dimensions7 pass

The introduction cites prior research on PPH as a leading cause of maternal death, the inaccuracy of visual blood loss estimation, and the delayed/inconsistent use of effective interventions. It acknowledges limitations of prior work, such as the late administration of tranexamic acid and low uptake of recommendations. The rationale logically links these challenges to the study's objective of evaluating cost-effectiveness of early detection and bundled treatment.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior research on PPH burden, detection challenges, and the E-MOTIVE trial, and logically links this to the economic evaluation objectives.

Evidence

paraphrase[Introduction, paragraph 1]

“Postpartum hemorrhage (PPH), defined as blood loss ≥500 ml from the genital tract after childbirth, is the leading cause of maternal death worldwide, accounting for approximately 27% of maternal deaths.”

direct quote[Introduction, paragraph 4]

“In this Article, we report the economic evaluation conducted alongside the E-MOTIVE trial, an integral component of the E-MOTIVE project, which aimed to assess the cost-effectiveness of the E-MOTIVE intervention compared with usual care.”